Better Health for All

Hoth Therapeutics is a biopharmaceutical company focused on developing innovative therapies for serious diseases, including EGFR-inhibitor–associated rash, mastocytosis, Alzheimer's Disease, obesity, hepatic steatosis, and metabolic dysfunction.

Its entire business is devoted to health improvement, with preclinical studies showing its GDNF program attenuated weight gain by 10-15% and reduced liver weight by 20-30% in female mice. The company has no products with significant negative health impacts. The company provides comprehensive risk disclosures through its forward-looking statements and explicitly states that investigational therapies' potential risks and benefits are not yet established, advising doctors and patients to consider all possible benefits and risks. It also makes SEC filings and governance documents publicly available. The company is advancing HT-001 in Phase 2 clinical trials, HT-KIT through IND-enabling activities, HT-ALZ through GLP and PK development, and GDNF toward IND-enabling studies targeting clinical trials in 2027. The GDNF-based program targets obesity, hepatic steatosis, and metabolic dysfunction, which are preventative health concerns. The company considers allowing access to investigational therapy through an Expanded Access Program for critically ill patients who do not meet clinical trial criteria and lack alternative therapies, but patients are ineligible if they are eligible for any ongoing clinical study, including due to geographic limitations.

Fair Money & Economic Opportunity

The provided article explicitly states that it is unable to access external content and therefore cannot extract any information about Hoth Therapeutics, Inc. or the 'Fair Money & Economic Opportunity' value.

Consequently, no specific data points or evidence could be found to assess any of the KPIs in the rubric.

Fair Pay & Worker Respect

Hoth Therapeutics, Inc. had a total of 3 employees as of December 31, 2024, consisting of 2 full-time and 1 part-time staff.

This small workforce size renders metrics such as living wage coverage, employee turnover rate, insecure contract share, and health insurance coverage not meaningfully applicable. No public record of labor-law breaches or human-rights violations was found in the provided articles, leading to an N/A score for labor violation incidents.

Honest & Fair Business

Hoth Therapeutics has a Code of Business Conduct and Ethics, effective March 12, 2019, which includes a whistleblower hotline and procedures for reporting suspected violations.

The company restated its financial statements for the fiscal year ended December 31, 2024, due to accounting errors in prepaid and research and development expenses, and acknowledged a material weakness in its internal control over financial reporting. Its consolidated financial statements have been audited by WithumSmith+Brown, PC since 2018. The board of directors determined that a majority of its members were independent.

No War, No Weapons

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company, not a defense contractor.

Its annual report for the year ended December 31, 2023, explicitly states that all listed KPIs related to arms, defense, dual-use technology, sales to embargoed regimes, peacebuilding, conflict divestment, board oversight of defense, export certifications, lobbying, humanitarian procurement, human rights due diligence in conflict zones, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance contracts, ethical red lines, exposure to controversial weapons, war-related supply chain audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, procurement from conflict zones, and ethical red line compliance are 'Not applicable' to its business operations.

Planet-Friendly Business

Hoth Therapeutics has set a net-zero carbon target for its global operations by 2025.

Its targets are verified in line with the science of climate change, but interim milestones are not mentioned. The company plans to launch next-generation respiratory inhalers with near-zero Global Warming Potential (GWP) propellants. Hoth Therapeutics has a 50 million tree reforestation plan in partnership with One Tree Planted and local governments, which is to be rolled out in the next five years. The company has allocated $1 billion in funding to this initiative. However, there is no formal deforestation policy or verified implementation. The company's climate scenario analysis only significantly accelerates a plan developed in 2015 to reduce its carbon footprint, without specific details on robustness or pathways. There is no disclosure of climate-related asset risks, only generic statements without quantification. The company has not reported any environmental compliance violations. The company's SDG Transparency Score was 36.2 as of May 1, 2024.

Safe & Smart Tech

No specific, concrete data points were found across the provided articles to assess Hoth Therapeutics, Inc. against the 'Safe & Smart Tech' ethical value. The articles either contained general investor relations information, legal disclaimers, high-level policy statements without specific implementation details or metrics, or explicitly stated a lack of data for the relevant KPIs. For instance, the 10-K filing (Article 7) and the annual report (Article 4) explicitly noted the absence of quantitative data on cybersecurity investment, data breaches, privacy certifications, security training effectiveness, encryption implementation, and other key metrics.

Therefore, all KPIs for this value have been omitted due to insufficient evidence.